GCM
CHRS icon

Glenview Capital Management’s Coherus Oncology CHRS Stock Holding History

Glenview Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-426,738
Closed -$6.92M – 46
2020
Q1 		$6.92M Buy
+426,738
New +$7.88M 0.19% 39

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Glenview Capital Management's CHRS Position: Q2 2020 in Review

Glenview Capital Management sold out of Coherus Oncology (CHRS) in Q2 2020, closing a stake of 426,738 shares — an estimated $6.92M sold.

Glenview Capital Management first reported a position in CHRS in Q1 2020 and held it in 1 quarter. The position peaked at $6.92M in Q1 2020. 188 funds tracked by Wall St. Rank hold CHRS as of Q2 2020.

  • Glenview Capital Management reported no remaining Coherus Oncology position as of Q2 2020 after selling out during the quarter.
  • Glenview Capital Management sold 426,738 Coherus Oncology shares in Q2 2020, an estimated $6.92M.
  • Glenview Capital Management first reported a position in Coherus Oncology in Q1 2020 and held it in 1 quarter.
  • Glenview Capital Management's Coherus Oncology position peaked at $6.92M in Q1 2020.
  • 188 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2020.

Based on Glenview Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.